Compliance Certificate For Half Year Ended September 30,2018
Compliance Certificate under regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements)Regulations,2015 for half year ended September 30,2018.12-10-2018
12-10-2018
Board Meeting Intimation for BOARD MEETING FOR CONSIDERING THE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED SEPTEMBER 30,2018
CAPLIN POINT LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2018 ,inter alia, to consider and approve BOARD MEETING FOR CONSIDERING THE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER/HALF YEAR ENDED SEPTEMBER 30,201809-10-2018
Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Caplin Point Laboratories Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here01-10-2018
VOTING RESULTS OF THE 27TH ANNUAL GENERAL MEETING HELD ON SEPTEMBER 28, 2018
Pursuant to Regulation 44 of SEBI(Listing Obligations and Disclosure Requirements) Regulations,2015, herewith, we enclose the voting results along with the Scrutinizer Report for the business transacted at the 27th Annual General Meeting of the members held on September 28,2018.30-09-2018
SUMMARY OF PROCEEDINGS OF 27TH ANNUAL GENERAL MEETING HELD ON SEPTEMBER 28,2018
SUMMARY OF PROCEEDINGS OF 27TH ANNUAL GENERAL MEETING HELD ON SEPTEMBER 28,201829-09-2018
Caplin Point, Hainan Jointown Pharma sign jt venture pact
Caplin Point Laboratories and Hainan Jointown Pharmaceutical Company had signed a joint venture agreement for establishing a company - Hainan Jointown14-09-2018
Announcement under Regulation 30 (LODR)-Joint Venture
Further to our press release dated August 06,2018, we wish to inform exchanges that Caplin Point Laboratories Limited and Hainan Jointown Pharmaceutical Company Limited, China had signed a Joint Venture agreement for establishing a Joint Venture Company named Hainan Jointown Caplinpoint Pharmaceutical Company Limited in Haikou City of China.14-09-2018
SUCCESSFUL US FDA INSPECTION AT STERILE INJECTABLE SITE (CP IV) AT GUMMUDIPOONDI
We are pleased to inform you that the United States Food and Drug Administration (US FDA) has conducted an inspection at our STERILE INJECTABLE SITE (CP - IV) located at Gummudipoondi from August 30, 2018 to September 06,2018. This was a scheduled inspection and at the end of the inspection, there were ZERO 483s07-09-2018
Notice Convening The 27Th Annual General Meeting.
Notice convening the 27th Annual General Meeting.04-09-2018